Soleno Therapeutics Inc Stock
Soleno Therapeutics Inc Stock price
Key metrics
| Market capitalization | $2.23b |
| Enterprise Value | $1.98b |
| P/E (TTM) P/E ratio | negative |
| EV/FCF (TTM) EV/FCF | negative |
| P/B ratio (TTM) P/B ratio | 8.03 |
| Revenue (TTM) Revenue | $0.00 |
| EBIT (operating result TTM) EBIT | $-138.47m |
| Free Cash Flow (TTM) Free Cash Flow | $-51.63m |
| Cash position | $256.78m |
Is Soleno Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.
Soleno Therapeutics Inc Stock Analysis
Analyst Opinions
8 Analysts have issued a Soleno Therapeutics Inc forecast:
Analyst Opinions
8 Analysts have issued a Soleno Therapeutics Inc forecast:
Financial data from Soleno Therapeutics Inc
| Sep '24 |
+/-
%
|
||
| Revenue | - - |
-
|
|
| Gross Profit | -1.97 -1.97 |
12%
12%
|
|
| EBITDA | -137 -137 |
358%
358%
|
EBIT (Operating Income) EBIT | -138 -138 |
332%
332%
|
| Net Profit | -131 -131 |
295%
295%
|
|
In millions USD.
Don't miss a Thing! We will send you all news about Soleno Therapeutics Inc directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Soleno Therapeutics Inc Stock News
Company Profile
Soleno Therapeutics, Inc. engages in the development and commercialization of novel therapeutics for the treatment of rare diseases. The company focuses on the treatment of metabolic and neurobehavioral disorder. It offers its lead candidate, Diazoxide Choline Controlled-Release (DCCR), an oral tablet for the treatment of Prader-Willi Syndrome (PWS). The company was founded on August 25, 1999 and is headquartered in Redwood City, CA.
| Head office | United States |
| CEO | Anish Bhatnagar |
| Employees | 42 |
| Founded | 1999 |
| Website | www.soleno.life |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
